SynthesisJAMA oncology2020

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.

Jianchun Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.